OncoMatch/Clinical Trials/NCT06563362
Personalized Volume-deescalated Elective Nodal Irradiation in Oropharyngeal Head and Neck Squamous Cell Carcinoma
Is NCT06563362 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for oropharynx cancer.
Multicentric prospective model-based de-escalation of the elective clinical target volumes (CTV) in radiotherapy of oropharyngeal carcinoma of all stages with the goal to reduce toxicity. The study investigates the feasibility of this approach as measured by the number of expected out-of-field recurrencies based on the individual patient's state of disease progression and risk factors
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: surgery
Exception: Dissection of singular lymph nodes for diagnostic purposes before treatment start is allowed.
Previous surgery in head and neck region affecting the cervical lymphatic system. Dissection of singular lymph nodes for diagnostic purposes before treatment start is allowed.
Cannot have received: chemotherapy
Previous chemotherapy treatment for other head and neck cancers.
Cannot have received: radiotherapy
Previous radiotherapy treatment for other head and neck cancers.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify